CDC42 and neoplasm: Calvo et al. have demonstrated that RasGRF2 also plays a role in modulating tumor cell movement and invasion by inhibiting the activation of cell division control protein 42 (Cdc42), a key component of actomyosin‐contractility‐dependent tumor cell movement.3